Abeona Therapeutics Inc.

NASDAQ:ABEO

Biotechnology

Healthcare
$2.73 +1.06%

+$0.06 today

Market cap
$156.01M
Beta
1.35
P/E (TTM)
4.9
EPS (TTM)
$1.17
52W Low $4.00High $7.54

Volume 1.71M

Average 1.12M

ABEO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Abeona Therapeutics Inc.NASDAQ: ABEO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $2.96M rose 9.5% year over year, ahead of the +7.1% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +52.3% a year.

Context

  • Stock-based compensation amounted to 185.2% of revenue in FY2025.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +9.5% holds above the trailing-twelve-month pace of +7.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.96M+2182.4% QoQ
Last fiscal yearDec 2025
$10.78M+62.6% YoY
LTMMar 2026
$8.33M+7.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.5%——
1 year+62.6%——
3-year CAGR+52.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
10.78M USD
Year-over-year change
+62.6%
4-year CAGR
+4.9%

Stock-Based Compensation vs competitors

How ABEO compares with its peers on the latest reported figures

  • ABEO's LTM Mar 2026 stock-based compensation of $8.33M is the 6th largest of the 10 companies compared; the peer median is $9.79M.
  • Its year-over-year change of +7.1% is the 5th highest of 10, against a peer median of -8.6%.
  • Stock-based compensation amounts to 57.3% of revenue for ABEO, versus a peer median of 37.3%.
ABEO Competitors Peer median
Stock-Based Compensation for ABEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$23.07M -33.2%-6.0%50.9%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$13.6M -8.6%+16.5%37.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$11.51M -28.1%+4.4%5116.0%
HUMAHumacyte, Inc.LTM Mar 2026$10.44M +45.6%+16.4%517.7%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$9.79M -31.5%+8.6%—
ABEOAbeona Therapeutics Inc.LTM Mar 2026$8.33M +7.1%+52.3%57.3%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.36M +42.2%—26.1%
SGMTSagimet Biosciences Inc.LTM Mar 2026$6.82M +13.6%+50.8%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$6.81M -13.7%-16.3%3.0%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$5.08M +64.3%-10.8%7.1%
Peer median (excluding ABEO) $9.79M-8.6%+6.5%37.3%

Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(84.94M)(39.7M)(54.19M)(63.73M)71.18M
Depreciation & Amortization4.46M4.58M3.2M2.91M3.56M
Deferred Income Tax00000
Stock-Based Compensation8.92M3.05M4.77M6.63M10.78M
Change in Working Capital(18.26M)(5.89M)(1.79M)(4.38M)(5.39M)
Accounts Receivables(3M)2.81M(2.04M)792K(5.06M)
Inventory0000(5.49M)
Accounts Payables(15.59M)(9.11M)2.04M(3.49M)6.54M
Other Working Capital324K404K(3.83M)(1.68M)(1.37M)
Other Non-Cash Items24.15M(5.52M)11M2.57M(156.46M)
Operating Cash Flow(65.67M)(43.48M)(37.01M)(56.02M)(76.33M)
Capital Expenditures(4.15M)(130K)(331K)(2.45M)(7.98M)
Acquisitions (Net)00000
Purchases of Investments(20.16M)(78.21M)(51.64M)(157.01M)(206.63M)
Sales of Investments90.38M52.64M51.97M120.2M167.27M
Other Investing Activities01.73M204K18K152.37M
Investing Cash Flow66.06M(23.96M)208K(39.24M)105.03M
Debt Repayment00020M0
Common Stock Issued24.03M46.96M37.39M85.63M26.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities831K(5K)(332K)(1.49M)(37K)
Financing Cash Flow24.86M43.17M37.06M104.14M26.04M
Effect of Forex Changes00000
Net Change in Cash25.26M(24.27M)256K8.88M54.74M
Free Cash Flow(69.82M)(43.61M)(37.34M)(58.46M)(84.3M)

Abeona Therapeutics Inc.

NASDAQ:ABEO

Intrinsic Alpha fair value

Locked

Current Price

$2.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.